Report
Alex Morozov
EUR 101.80 For Business Accounts Only

The CareFusion acquisition opens up a new epoch for BD.

Becton, Dickinson and Co.’s fourth-quarter 4.4% organic revenue growth (adjusted for the respiratory sale and a change to the U.S. dispensing business model) came in above our expectations. The firm's 2018 guidance is calling for performance at the higher end of our expectations, as BD is intent on delivering on its growth initiatives, as outlined during its last year's analyst day. Our narrow moat and stable trend ratings are intact. We anticipate a modest upward revision to our $193 fair value...
Underlying
Becton Dickinson and Company

Becton, Dickinson and Company is a medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The company's segments are: BD Medical, which produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings; BD Life Sciences, which provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers; and BD Interventional, which provides vascular, urology, oncology and surgical products.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Alex Morozov

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch